Pharmaceuticals

KMYY

KMYY released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 1.08 B, actual EPS CNY -0.001

KMYY to Release FY2026 Q1 Earnings on April 30 After-Market (BJT)

KMYY FY2025 Annual Earnings Release on April 18, 2026 After-Market (BJT)

KMYY released FY2025 Annual Earnings on March 31 After-Market (BJT), Actual Revenue: CNY 5.252 B, Actual EPS: CNY 0.0007

KMYY released FY2025 Q4 earnings on March 31 After-Market (BJT), actual revenue CNY 1.293 B, actual EPS CNY -0.0001

KMYY released FY2025 Q3 earnings on October 30 Pre-Market (BJT), actual revenue CNY 1.382 B, actual EPS CNY -0.0002

KMYY released FY2025 9 Months Earnings on October 30 Pre-Market (BJT), actual revenue CNY 3.96 B, actual EPS CNY 0.0005

KMYY to Release FY2025 Q3 Earnings on October 31, Pre-Market BJT

KMYY released FY2025 Semi-Annual Earnings on August 29 During-Market (BJT), actual revenue CNY 2.577 B, actual EPS CNY 0.0012

KMYY released FY2025 Q2 earnings on August 29 During-Market (BJT), actual revenue CNY 1.278 B, actual EPS CNY 0.0003

KMYY FY2025 Semi-Annual Earning Release on August 30, 2025 (BJT)

Kangmei Pharmaceutical Reaches a 43.5 Million Yuan Settlement with GMP Group

Kangmei Pharmaceutical Secretary Responds to Investor Queries on Business and E-commerce Platforms

Kangmei Pharmaceutical Updates on Ginseng Planting Progress

KMYY released FY2025 Q1 earnings on April 29 After-Market BJT, actual revenue CNY 1.299 B, actual EPS CNY 0.001

KMYY FY2025 Q1 Earnings Release Scheduled for April 30 After-Market BJT

Kangmei Pharmaceutical Announces 2024 Net Profit Down 91.64%, No Dividend

KMYY released FY2024 Annual Earnings on April 18 After-Market (BJT), actual revenue CNY 5.189 B, actual EPS CNY 0.0006

KMYY released FY2024 Q4 earnings on April 18 After-Market (BJT), actual revenue CNY 1.316 B, actual EPS CNY 0.0002

KMYY FY2024 Annual Earnings Release Scheduled for April 19, 2025, After-Market BJT

The global stigmasterol-rich plant sterols market is projected to reach USD 1,281.42 million by 2036, driven by rising cardiovascular health awareness and demand for functional foods. The market is transitioning towards standardized formulations and regulatory support, with significant growth in applications across food, nutraceuticals, and pharmaceuticals. Key growth regions include India, Germany, and China, with a forecast CAGR of 3.8% from 2026 to 2036. The market is bolstered by increasing consumer preference for plant-based wellness solutions and regulatory approvals for health claims.

MorningStar

Stigmasterol-Rich Plant Sterols Market to Reach USD 1,281.42 Million by 2036 as Cardiovascular Health Awareness and Functional Food Demand Expand Globally

Senate Minority Leader Chuck Schumer criticized Donald Trump's recent trip to China, labeling it a 'photo op' that failed to address key issues such as fentanyl, Taiwan, U.S. manufacturing, and AI. Schumer stated that Trump returned with 'nothing to show for it' and highlighted concerns over the lack of action on fentanyl flow, protections for U.S. manufacturers, and doubts regarding U.S. commitment to Taiwan.

benzinga_article

NVIDIA

Alibaba

BABA-W

TENCENT

Tencent

NVIDIA Corporation

BABA-WR

Alibaba HK SDR 5to1

TENCENT-R

Tencent HK SDR 10to1

Tencent Holdings Limited

Chuck Schumer Slams Trump China Trip As 'Photo Op' With Xi Jinping, Says Visit Delivers 'Nothing' On Fentanyl, Taiwan And AI

600703

600518

601600

601012

The Shangai Composite Index decreased -38 points or 0.96 percent on Friday to close at 3882 points.The decline was led by Kangmei Pharma (-4.37%), LONGi Green (-3.97%) and Aluminum Corporation of China (-3.94%).On the upside, the strongest performers were China Fortune (6.06%), Sanan Optoelectron (2.89%) and Inner Mongolia BaoTou Steel (1.91%).

Trading Economics

SANAN

CHALCO

LONGi

The Shangai Composite Index Closes 0.96% Lower

According to the Zhitong Finance APP, KMYY disclosed its third-quarter report for 2025, stating that the company achieved revenue of 3.96 billion yuan in the first three quarters, a year-on-year increase of 2.22%; net profit attributable to the parent company was 13.08 million yuan, a year-on-year increase of 160.84%; the net profit excluding non-recurring gains and losses was a loss of 37.94 million yuan; basic earnings per share were 0.001 yuan

Zhitong

KMYY released its performance for the first three quarters, with a net profit attributable to the parent company of 13.08 million yuan, a year-on-year increase of 160.84%

According to the Zhitong Finance APP, KMYY disclosed its semi-annual report for 2025, stating that the company achieved revenue of 2.577 billion yuan during the reporting period, a year-on-year increase of 4.17%; net profit attributable to the parent company was 16.9 million yuan, a year-on-year increase of 7.24%; the net profit excluding non-recurring items was a loss of 3.62 million yuan; basic earnings per share were 0.001 yuan

KMYY released its semi-annual performance, with a net profit attributable to the parent company of 16.9 million yuan, a year-on-year increase of 7.24%

KMYY announced that its wholly-owned subsidiary Chengdu KMYY Pharmaceutical Co., Ltd. intends to sign a settlement agreement with Guangzhou Pharmaceutical Group Co., Ltd. to settle the aforementioned debt with 43.5 million yuan and related handling fees. After the payment is completed, the Guangzhou Pharmaceutical Group will assist Chengdu KMYY in handling the execution unsealing and case closure procedures. This transaction constitutes a related party transaction but does not constitute a major asset reorganization

KMYY: Plans to sign a settlement agreement with related party Guangzhou Pharmaceutical Group to resolve historical debt issues for 43.5 million yuan

On the afternoon of May 23, Ou Guoxiong, director and general manager of KMYY, responded to the ginseng planting situation at the 2024 annual performance briefing, stating that as of December 31, 2024, the company's subsidiary Jianshan Dadi Ginseng Industry Co., Ltd. has accumulated a total of 51,200 acres of land in circulation, with a cumulative fresh ginseng harvesting area of 36,500 acres, a current ginseng planting area of 14,700 acres, and an additional 2,000 acres of land available for planting. The ginseng planting and harvesting work is progressing smoothly

KMYY: The current ginseng planting area is 14,700 acres

According to the Zhitong Finance APP, KMYY released its 2024 annual report, stating that the company's operating revenue for 2024 was 5.189 billion yuan, a year-on-year increase of 6.47%; the net profit attributable to shareholders of the listed company was 8.5737 million yuan, a year-on-year decrease of 91.64%; the net loss attributable to shareholders of the listed company, after deducting non-recurring gains and losses, was 533 million yuan, with losses narrowing; the basic earnings per share were 0.0006 yuan/share

KMYY released its 2024 annual performance, with a net profit attributable to shareholders of RMB 8.5737 million, a year-on-year decrease of 91.64%

On the evening of February 17th, KMYY announced that the company held the first extraordinary meeting of the 10th Board of Directors for the year 2025, electing Lai Zhijian as the chairman of the 10th Board of Directors

KMYY: Elected Lai Zhijian as the company's chairman

KMYY(600518.SH)